OMAN MOH issued new Circular No. 51/2026 – Suspension of Receiving Medicines and Biological Products Registration Files

🔍 What’s new:
The Drug Safety Center announced a temporary suspension on accepting new medicine registration applications for certain products to align with updated local market regulatory requirements.

Key points include:

• Products manufactured by national pharmaceutical manufacturers are excluded from the temporary suspension.
• The suspension applies where the percentage of Omani ownership in the commercial registration of the local agent or the actual beneficiary of the registration, marketing, or distribution is less than 100%.
• The suspension period is three (3) months and may be renewable as necessary.
• The suspension takes effect from 18 May 2026.

💡 Required Industry Action / Relevance:

Local agents and pharmaceutical companies operating in Oman should assess ownership structures and evaluate the potential impact on current or future medicine registration activities during the temporary suspension period.

📨 ReguLinked keeps you updated with timely regulatory intelligence and practical compliance insights across Oman and the GCC.

“Book your complimentary consultation today”

📧 BD@regulinked.com | 🌐 www.regulinked.com

🔗 Official Circular (PDF): Circular No. 51/2026 – Suspension of Receiving Medicines and Biological Products Registration Files

#ReguLinked #OmanMoH #RegulatoryUpdate #MarketAccess #Compliance